Navigation Links
VisEn Launches New VivoTag(R) 645 Fluorescence Molecular Imaging Label
Date:5/5/2010

BEDFORD, Mass., May 5 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new VivoTag® 645 red fluorescent dye for optimized labeling of biomolecules in a broad range of in vitro and in vivo research applications.  

The new VivoTag 645 represents VisEn's first agent offering in the lower-red wavelengths, enabling optimized and integrated imaging applications in both in vivo and in vitro research areas.  The VivoTag 645 is specifically designed for efficient and robust labeling of biomolecules, and is optimized for broad in vitro and in vivo imaging performance, including system compatibility, superior brightness, biocompatibility and stability in biological environments.  

"Our new VivoTag 645 represents an important evolution in our fluorescent imaging agent product line," said Kirtland Poss, President and CEO of VisEn Medical. "This new label is designed to be well-suited for applications both in vitro and in vivo research and we look forward to working closely with our customers in continually advancing these integrated research areas."

The new VivoTag 645 is particularly well suited for labeling and imaging of proteins, antibodies, and small molecules in a range of research areas.  The fluorescence wavelength is matched for biological imaging applications on in vitro and in vivo fluorescence systems, including advanced microscopes, high content imaging and flow cytometry systems. It is also optimized for use with VisEn's fluorescence tomography FMT™ imaging systems which also have expanded wavelength capabilities to enable quantitative imaging of up to four channels and four different biomarkers of interest in vivo.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts.  VisEn offers over 35 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways.  VisEn agent brands include ProSense®, IntegriSense™, AngioSense™, OsteoSense®, MMPSense™, GastroSense™, ReninSenseTM, Annexin-VivoTM, and the FAST™ line of imaging agents including Cat K FAST™ and Cat B FAST™.  VisEn also offers specialized lines of agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes and its NanoSpark® nanoparticles for customized fluorescence agent labeling.  They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in biological imaging applications including in vitro, cell, tissue and in vivo imaging applications.  

All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems.  VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and other cellular-based imaging systems.  With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking preclinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its RED Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo.  VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease.  The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific preclinical and clinical research areas. Additional information can be found at www.visenmedical.com.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent
2. VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent
3. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
4. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
5. VisEn Medical Raises $7 Million in Series B Financing
6. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
7. BellBrook Labs Launches Compound Profiling Services with High Content 3D Invasion Assay
8. Ansell Launches Worldss First Antimicrobial Surgical Glove
9. ChromaDex Launches pTeroPure Pterostilbene
10. Vermont Launches Renewable Energy Atlas
11. DNA-Planet Launches New Service for Customer-Individual Indirect DNA Paternity Testing and Kinship Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... and commercializing products to treat rare diseases where there ... will be hosting an Investor Webcast Event Friday, December ... of innate defense regulators (IDRs) as a new drug ... and the recently announced and published Phase 2 clinical ...
(Date:12/8/2016)...   Biocept, Inc . (NASDAQ: ... actionable liquid biopsy tests to improve the management ... its Target Selectorâ„¢ Circulating Tumor Cell platform demonstrated ... of actionable biomarkers in patients with metastatic breast ... Cannon Research Institute (SCRI), the research arm of ...
(Date:12/7/2016)... 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical ... immunotherapeutic products for the treatment of cancer, today ... Manufacturing Development Program with Cytovance Biologics ( ... oregovomab antibody product. Supported by recent positive interim ... in ovarian cancer patients, OncoQuest has engaged Cytovance ...
(Date:12/7/2016)... ROCHESTER, Minn. , Dec. 7, 2016  Vyriad ... McQuinn to the company,s Board of Directors. ... board as we build our business and develop our ... for cancer therapy," said Stephen Russell , MD, ... Mary Agnes , share our vision and passion for ...
Breaking Biology Technology:
(Date:11/15/2016)... 2016 Research and Markets has announced the ... report to their offering. ... The ... 2021 from USD 6.21 Billion in 2016, growing at a CAGR ... the bioinformatics market is driven by the growing demand for nucleic ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
Breaking Biology News(10 mins):